Compare AbbVie Inc (ABBV) vs DraftKings Inc (DKNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs DraftKings Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while DraftKings Inc trades at $27.32 (market cap $13.35B). The key difference: AbbVie Inc is far larger — about 33.7× DraftKings Inc's market cap, and AbbVie Inc pays a 2.72% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals.
| ABBV | DKNG | |
|---|---|---|
Market Cap | $449.91B | $13.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $48.23 |
52-Week Low | $184.85 | $20.72 |
Enterprise Value | $513.38B | $14.27B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
DraftKings (DKNG) trades at $26.91, up 3.94% today, with a bearish technical signal but strong analyst consensus. Revenue grew to $6.05B in 2025, achieving positive net income of $3.71M, a significant turnaround from prior losses. The launch of the DKeX prediction market exchange (Business Wire, 2026-06-26) and record sportsbook engagement during the 2026 World Cup (Benzinga, 2026-06-26) highlight growth initiatives, though profitability remains thin with a P/E of 291.22.
The outlook is mixed: robust revenue growth and a $34.25 analyst price target suggest upside, but high valuation, competitive pressures, and regulatory risks pose challenges. Positive cash flow from operations of $662.86M in 2025 supports stability, yet volatility near key resistance at $27 requires monitoring for sustained bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →
